Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,601–1,700 of 2,576
Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer’s disease
Galasko, D. R. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_19 · Cited by 22
Lessons from genome‐wide association studies findings in Alzheimer's disease
Moraes, C. F., Lins, T. C. D. L., CARMARGOS, E. F., Naves, J. O. S., Pereira, R. W., & Nóbrega, O. D. T. (2011) · Psychogeriatrics · doi:10.1111/j.1479-8301.2011.00378.x · Cited by 22
Supramolecular Structures of Amyloid-Related Peptides in an Ambient Water Nanofilm
Ye, M., Zhang, Y., Li, H., Xie, M., & Hu, J. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp105501x · Cited by 19
Kainic acid hyperphosphorylates tau via inflammasome activation in MAPT transgenic mice
Zheng, X., Lv, Y., Jin, F., Wu, X., Zhu, J., & Ruan, Y. (2019) · Aging · doi:10.18632/aging.102495 · Cited by 21
Llibre‐Guerra, J. J., Iaccarino, L., Coble, D., Edwards, L., Li, Y., McDade, E., Strom, A., Gordon, B. A., Mundada, N. S., Schindler, S. E., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad280 · Cited by 21
Peng, X.-L., Hou, L., Xu, S., Hua, Y., Zhou, S.-J., Zhang, Y., Zheng, Y.-P., Fu, Y.-H., Xu, Q., Zhang, L.-S., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.005 · Cited by 21
Alzheimer's disease: Genetic evidence points to a single pathogenesis
Hardy, J. (2003) · Annals of Neurology · doi:10.1002/ana.10624 · Cited by 20
“Mutations in the APP and presenilin genes appear to cause disease by subtly altering APP processing in such a way that A deposition is more likely.(5) These findings have provided the underpinning of the amyloid hypothesis.”
BackgroundSelf-citationCellular prion protein modulates β-amyloid deposition in aged APP/PS1 transgenic mice
Ordóñez‐Gutiérrez, L., Torres, J. M., Gavín, R., Antón, M., Arroba, A. I., Espinosa, J. C., Vergara, C., del Río, J. A., & Wandosell, F. G. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.019 · Cited by 24
Alzheimer's Disease: Characterization, Evolution and Implications of the Neuroinflammatory Process
Viegas, F. P. D., Simões, M. C. R., da Rocha, M. D., Castelli, M. R., Moreira, M. S., & Junior, C. V. (2011) · Revista Virtual de Química · doi:10.5935/1984-6835.20110034 · Cited by 36
Nguyen, H. L., Thu, T. T. M., Tu, L., Hu, C., & Li, M. S. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b12888 · Cited by 19
Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy
Nieznańska, H., Bandyszewska, M., Surewicz, K. A., Zajkowski, T., Surewicz, W. K., & Nieznański, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.023 · Cited by 22
Vidal, C., & Li, Z. (2021) · Cells · doi:10.3390/cells10030546 · Cited by 21
Elsworthy, R. J., King, M. C., Grainger, A. I., Fisher, E., Crowe, J. A., Alqattan, S., Ludlam, A., Hill, E. J., & Aldred, S. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103631 · Cited by 22
Rajpoot, J., Crooks, E. J., Irizarry, B. A., Amundson, A., Nostrand, W. E. V., & Smith, S. O. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00781 · Cited by 22
Warrington, E. K., Agnew, S. K., Kennedy, A. M., & Rossor, M. N. (2001) · Journal of Neurology · doi:10.1007/s004150170268 · Cited by 22
“The exact mechanism by which mutations in the PS–1 gene leads to AD is still not established although the current evidence suggests an increase in the proportion of Aβ1–42 as opposed to Aβ1–40 [35, 36].”
BackgroundRecent Understanding of the Molecular Mechanisms of Alzheimer?s Disease
Grimm, M. O. W., & Hartmann, T. (2011) · Journal of Addiction Research & Therapy · doi:10.4172/2155-6105.s5-004 · Cited by 25
Substrate recruitment by γ-secretase
Fukumori, A., Feilen, L. P., & Steiner, H. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.006 · Cited by 22
Disordered proteins in dementia
Ingelsson, M., & Hyman, B. T. (2002) · Annals of Medicine · doi:10.1080/078538902320322529 · Cited by 20
Alternative splicing in the N-terminus of Alzheimer?s presenilin 1
Scheper, W., Zwart, R., & Baas, F. (2004) · Neurogenetics · doi:10.1007/s10048-004-0195-y · Cited by 19
Inhibition of β-amyloid formation as a therapeutic strategy
Moore, C. L., & Wolfe, M. S. (1999) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.9.2.135 · Cited by 21
Amyloid precursor protein gene isoforms in Alzheimer’s disease and other neurodegenerative disorders
Panegyres, P. K., Toufexis, K., & Kakulas, B. A. (2000) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00311-1 · Cited by 21
Erbliche Ursachen und Risikofaktoren der Alzheimer-Krankheit
Lautenschlager, N. T., Kurz, A., & Müller, U. (1999) · Der Nervenarzt · doi:10.1007/s001150050423 · Cited by 23
APP Gene Promoter Constructs Are Preferentially Expressed in the CNS and Testis of Transgenic Mice
Fox, N. W., Johnstone, E. M., Ward, K. E., Schrementi, J. P., & Little, S. P. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7728 · Cited by 19
McMillan, P. J., Leverenz, J. B., & Dorsa, D. M. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00086-3 · Cited by 19
Yliopisto, K., & Helisalmi, S. (1998) · Cited by 33
Collection and normal levels of the amyloid precursor protein in plasma
Whyte, S., Wilson, N., Currie, J., Maruff, P. T., Malone, V., Shafiq-Antonacci, R., Tyler, P., Derry, K. L., Underwood, J. R., Li, Q., et al. (1997) · Annals of Neurology · doi:10.1002/ana.410410122 · Cited by 20
Michno, W., Blennow, K., Zetterberg, H., & Brinkmalm, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15466 · Cited by 19
“Although plasma A β analysis using immunoassays was first reported in 1996 (Scheuner et al., 1996), the first publication using MS was in 2014 when Kaneko et al. The driving force behind the attempts to analyze A β in plasma by MS was the lack of suitable plasma biomarkers for AD.”
MethodA Perspective on the Potential Involvement of Impaired Proteostasis in Neuropsychiatric Disorders
Hui, K. K., Endo, R., Sawa, A., & Tanaka, M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.09.001 · Cited by 18
Navarro‐Hortal, M. D., Romero‐Márquez, J. M., Osta, S., Jiménez-Trigo, V., Muñoz-Ollero, P., & Varela‐López, A. (2022) · Diseases · doi:10.3390/diseases10020028 · Cited by 19
Getting ahead of Alzheimer’s disease: early intervention with focused ultrasound
Noel, R. L., Gorman, S. L., Batts, A. J., & Konofagou, E. E. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1229683 · Cited by 21
“In particular, mutations in presenilin 1 and 2 (PSEN1 and PSEN2), as well as APP have been linked to elevated levels of secreted Aβ protein (Scheuner et al., 1996; Mendez, 2012; Barage and Sonawane, 2015; Ju and Tam, 2021).”
BackgroundTian, Y., Shang, Q., Liang, R., & Viles, J. H. (2024) · JACS Au · doi:10.1021/jacsau.3c00687 · Cited by 19
C. elegans : a prominent platform for modeling and drug screening in neurological disorders
Romussi, S., Giunti, S., Andersen, N., & Rosa, M. J. D. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2329103 · Cited by 20
“EOAD involves mutations in the presenilin 1 and 2 or Aβ-protein precursor (APP) genes [84,85].”
BackgroundGalasko, D., Farlow, M. R., Lucey, B. P., Honig, L. S., Elbert, D. L., Bateman, R. J., Momper, J. D., Thomas, R. G., Rissman, R. A., Pa, J., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01490-z · Cited by 24
Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases
Wu, Y.-F., Ma, B., Liu, C. Y., Li, D., & Sui, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810187 · Cited by 25
“Mutations of PSEN1/2 can increase the A β 42/A β 40 ratio and consequently cause familial AD with an early-age onset of the disease [44–47].”
BackgroundLoss of Presenilin 2 Function Is Associated with Defective LPS-Mediated Innate Immune Responsiveness
Agrawal, V., Sawhney, N., Hickey, E., & McCarthy, J. V. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9285-0 · Cited by 21
“In general, mutations in the PS proteins that cause earlyonset familial Alzheimer’s disease (FAD) lead to increased generation of γ-secretase cleavage products including amyloid-β peptides in in vitro and in vivo paradigms [12–15].”
BackgroundFAD Mutations in Amyloid Precursor Protein Do Not Directly Perturb Intracellular Calcium Homeostasis
Stieren, E. S., Werchan, W. P., Ayadi, A. E., Li, F., & Boehning, D. F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011992 · Cited by 19
Biological markers of Alzheimer's disease
Mehta, P. D., & Pirttilä, T. (2002) · Drug Development Research · doi:10.1002/ddr.10063 · Cited by 18
Association of aBACE1Gene Polymorphism with Parkinson’s Disease in a Norwegian Population
Lange, J., Lunde, K. A., Sletten, C., Møller, S. G., Tysnes, O., Alves, G. W., Larsen, J. P., & Maple‐Grødem, J. (2015) · Parkinson s Disease · doi:10.1155/2015/973298 · Cited by 26
“SNPs were further prioritized if located in a known regulatory or coding region, and/or associated with APP processing or with AD in previous studies (BACE [8, 15]; ADAM10 [9]; PSEN [10]; and CLU [16]).”
BackgroundFarnsworth, B., Peuckert, C., Zimmermann, B., JAZIN, E. E., Kettunen, P., & Emilsson, L. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160160 · Cited by 18
Volicer, L. (2020) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_10_20 · Cited by 22
Kaczmarczyk, L., Reichenbach, N., Blank-Stein, N., Jonson, M., Dittrich, L., Petzold, G. C., & Jackson, W. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-84887-2 · Cited by 18
PQBP1: The Key to Intellectual Disability, Neurodegenerative Diseases, and Innate Immunity
Tanaka, H., & Okazawa, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116227 · Cited by 19
Alzheimer's disease and related dementias
Hardy, J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139087711.003 · Cited by 18
Self-citationSelective Vulnerability of Synaptic Signaling and Metabolism to Nitrosative Stress
Mongin, A. A., Dohare, P., & Jourd’heuil, D. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4559 · Cited by 19
Kretner, B., Fukumori, A., Kuhn, P., Pérez‐Revuelta, B. I., Lichtenthaler, S. F., Haass, C., & Steiner, H. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12124 · Cited by 22
“This disease-underlying principle is reflected by the majority of early onset familial forms of AD that are caused by changes of the Ab42/Ab40 ratio because of mutations in PS1, its homolog PS2, and APP (Scheuner et al. 1996).”
BackgroundSerum β-Amyloid Correlates with Neuropsychological Impairment
Luis, C. A., Abdullah, L. I., Paris, D., Quadros, A., Mullan, M. A., Mouzon, B., Ait‐Ghezala, G., Crawford, F., & MULLAN, M. J. (2008) · Aging Neuropsychology and Cognition · doi:10.1080/13825580802411766 · Cited by 19
“Previously studies have shown that plasma Aβ1–42 is significantly elevated in individuals with presenilin 1 and 2, and APP mutations (Scheuner et al., 1996), in asymptomatic first-degree relatives of AD patients (ErtekinTaner et al., 2003) and in older Down syndrome patients (Mehta et al., 2003).”
BackgroundDifferential display analysis of presenilin 1-deficient mouse brains
Liauw, J., Nguyen, V. D., Huang, J., George‐Hyslop, P. S., & Rozmahel, R. F. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00491-6 · Cited by 20
Inflammation on the Mind: Visualizing Immunity in the Central Nervous System
Kang, S. S., & McGavern, D. B. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-93864-4_10 · Cited by 19
“The γ-secretase dictates the length of the subsequent Aβ polypeptide, and altered APP metabolism due to mutations in the presenilin components of the γ-secretase has been linked with disease (Scheuner et al. 1996).”
BackgroundPharmacotheraphy for Alzheimer’s disease
Knopman, D. S. (2001) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-001-0102-y · Cited by 19
“The finding that patients with familial AD due to mutations in the presenilin genes had elevated levels of Aβ in their brains suggested that presenilin was somehow involved in the trafficking of APP [ 29 ,30].”
BackgroundTransport of Drugs Across the blood–brain Barrier in Alzheimer‘s Disease
Nicolazzo, J. A., & Mehta, D. C. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.41 · Cited by 22
Evidence that glypican is a receptor mediating β-amyloid neurotoxicity in PC12 cells
Schulz, J. G., Megow, D., Reszka, R. C., Villringer, A., Einhäupl, K. M., & Dirnagl, U. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00220.x · Cited by 20
Using peptide nucleic acids as gene-expression modifiers to reduce β-amyloid levels
McMahon, B. M., Stewart, J. A., Fauq, A. H., Younkin, S. G., Younkin, L. H., & Richelson, E. (2002) · Journal of Molecular Neuroscience · doi:10.1007/s12031-002-0013-7 · Cited by 21
Self-citationStanyer, L., Betteridge, D. J., & Smith, C. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02646-7 · Cited by 19
Andersen, J. M., Myhre, O., Aarnes, H., Vestad, T. A., & Fonnum, F. (2003) · Free Radical Research · doi:10.1080/1071576021000046631 · Cited by 20
Biological Markers and the Treatment of Alzheimer's Disease
Galasko, D. R. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:119 · Cited by 19
“…of Aβ42 is fostered in autosomal dominant forms of AD, as shown in medium from cultured fibroblasts of patients with pathogenic APP, PS1, and PS2 mutations (Scheuner et al., 1996), and in transgenic mice expressing mutants of APP or PS. Plasma Aβ levels may provide insights about Aβ production.”
BackgroundLazo, N. D., Maji, S. K., Fradinger, E. A., Bitan, G., & Teplow, D. B. (2005) · Wiley eBooks · doi:10.1002/9783527619344.ch17 · Cited by 19
Structural and Chemical Biology of Presenilin Complexes
Johnson, D. S., Li, Y., Pettersson, M., & George‐Hyslop, P. S. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024067 · Cited by 21
“Missense mutations in the presenilins alter the relative abundance of amyloid-b (Ab) peptide species produced during presenilin-complexmediated cleavage of APP-C100 following BACE cleavage of APP (Scheuner et al. 1996; Citron et al. 1997; Chávez-Gutiérrez et al. 2012).”
BackgroundBhattacharya, A., Izzo, A., Mollo, N., Napolitano, F., Limone, A., Margheri, F., Mocali, A., Minopoli, G., Bianco, A. L., Maggio, F. D., et al. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040232 · Cited by 18
Ankeny, S. E., Bacci, J. R., Decourt, B., Sabbagh, M. N., & Mielke, M. M. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00658-x · Cited by 23
Vidal, R., Sammeta, N., Garringer, H. J., Sambamurti, K., Miravalle, L., Lamb, B. T., & Ghetti, B. F. (2012) · The FASEB Journal · doi:10.1096/fj.12-205542 · Cited by 18
Lee, S. L., Thomas, P., & Fenech, M. F. (2013) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21811 · Cited by 19
“Furthermore, Ab42 is increased in plasma of AD cases [Scheuner et al., 1996; Kosaka et al., 1997; Mayeux et al., 1999; Mayeux et al., 2003] and in vitro studies suggest that it could be cytotoxic to human cells [Iversen et al., 1995; Li et al., 1996] but evidence of its effects on chromosomal…”
BackgroundProgress Towards a Consensus on Biomarkers for Alzheimer‘S Disease: A Review of Peripheral Analytes
Rembach, A., Ryan, T. M., Roberts, B. R., Doecke, J. D., Wilson, W. J., Watt, A. D., Barnham, K. J., & Masters, C. L. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.59 · Cited by 20
Very early–onset sporadic Alzheimer's disease with a de novo mutation in the PSEN1 gene
Lou, F., Luo, X., Li, M., Ren, Y., & He, Z. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.12.026 · Cited by 18
Amyloids of multiple species: are they helpful in survival?
Upadhyay, A., & Mishra, A. (2018) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12399 · Cited by 26
“Alzheimer’s disease, the most common form of dementia, can be caused by mutations in several genes, e.g. amyloid precursor protein (Goate & Chartier-Harlin, 1991), tau (Hutton et al., 1998), apolipoprotein E (apoE) (Saunders et al., 1993), and presenilins (Scheuner et al., 1996).”
BackgroundThe GSM BPN-15606 as a Potential Candidate for Preventative Therapy in Alzheimer’s Disease
Prikhodko, O., Rynearson, K. D., Sekhon, T., Mante, M., Nguyen, P. D., Rissman, R. A., Tanzi, R. E., & Wagner, S. L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190442 · Cited by 18
Self-citationAβ and perlecan in rat brain: glial activation, gradual clearance and limited neurotoxicity
Holcomb, L. A., Gordon, M. N., Benkovic, S. A., & Morgan, D. (2000) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(99)00086-x · Cited by 20
Vestergaard, M. C. M., Kerman, K., & Tamiya, E. (2006) · Nanobiotechnology · doi:10.1007/s12030-006-0002-y · Cited by 22
Mocali, A., Malva, N. D., Abete, C., Costanza, V. A. M., Bavazzano, A., Boddi, V., Sanchez, L. J., Dessì, S., Pani, A., & Paoletti, F. (2014) · International Journal of Alzheimer s Disease · doi:10.1155/2014/520152 · Cited by 20
“In fact, even Aβ peptides, the most sensitive and direct hallmark of AD, increase in plasma of rare dominant AD patients [53] but not in most common lateonset AD patients [54] who actually show a decline in Aβ-42 levels [9, 55].”
BackgroundAlleles at the Nicastrin locus modify presenilin 1- deficiency phenotype
Rozmahel, R. F., Mount, H. T. J., Chen, F., Nguyen, V., Huang, J., Erdebil, S., Liauw, J., Yu, G., Hasegawa, H., Gu, Y., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222413999 · Cited by 21
Azmi, N. H., Ismail, M., Ismail, N., Imam, M. U., Alitheen, N. B., & Abdullah, M. A. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/153684 · Cited by 26
Terrill, S. E., Colvin, B. A., Davenport, R. E., & Nichols, M. R. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.03.017 · Cited by 18
Burgos‐Ramos, E., Hervás‐Aguilar, A., Puebla‐Jiménez, L., Boyano-Adánez, M. D. C., & Arilla, E. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21115 · Cited by 19
APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease
Wolfe, M. S. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00179-0 · Cited by 24
Plasma β-amyloid (Aβ) 40 concentration, lipid status and age in humans
Smith, C., & Betteridge, D. J. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.05.081 · Cited by 18
Secretases as targets for drug design in Alzheimer’s disease
Hendriksen, J. V. R. B., Nottet, H. S. L. M., & Smits, H. A. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.00937.x · Cited by 17
Hossain, S., Grande, M., Ahmadkhanov, G., & Pramanik, A. (2007) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.01.008 · Cited by 19
Murphy, M. P., & Golde, T. E. (2006) · Neurology · doi:10.1212/01.wnl.0000192108.02654.ac · Cited by 21
Roberson, E. D. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-006-0050-7 · Cited by 24
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · Neurotherapeutics · doi:10.1007/bf03206606 · Cited by 28
Experimental Approaches to Cognitive Disturbance in Alzheimer's Disease
Samuels, S. C., & Davis, K. L. (1998) · Harvard Review of Psychiatry · doi:10.3109/10673229809010950 · Cited by 23
Neurons bearing presenilins: weapons for defense or suicide?
Popescu, B. O., & Ankarcrona, M. (2000) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2000.tb00124.x · Cited by 18
“Moreover, it was reported that PSs mutations carriers show a higher Aβ plasmatic level as compared to non-carriers [70].”
BackgroundPiccini, A., Fassio, A., Pasqualetto, E., Vitali, A., Borghi, R., Palmieri, D., Nacmias, B., Sorbi, S., Sitia, R., & Tabaton, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.11.013 · Cited by 20
Noninvasive Imaging of Peripherally Injected Alzheimer's Disease Type Synthetic Aβ Amyloid In Vivo
Marshall, J. R., Stimson, E. R., Ghilardi, J. R., Vinters, H. V., Mantyh, P. W., & Maggio, J. E. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010066z · Cited by 17
Transgenic models for Alzheimer's disease
Duff, K. (1998) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1998.00006.x · Cited by 17
Calenda, A., Mestre‐Francés, N., Czech, C., Pradier, L., Petter, A., Perret, M., Bons, N., & Bellis, M. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0205 · Cited by 20
Therapeutic targets in the biology of Alzheimerʼs disease
Bush, A. I. (2001) · Current Opinion in Psychiatry · doi:10.1097/00001504-200107000-00018 · Cited by 21
Molecular Identification of AMY, an Alzheimer Disease Amyloid-Associated Protein
Söderberg, L., Zhukareva, V. A., Bogdanović, N., Hashimoto, T., Winblad, B. G., Iwatsubo, T., Lee, V. M. ‐., Trojanowski, J. Q., & Näslund, J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.11.1108 · Cited by 17
“In addition, Ab can be detected as an apparent soluble peptide in human plasma and cerebrospinal fluid (8).”
BackgroundWanngren, J., Lara, P., Öjemalm, K., Maioli, S., Moradi, N., Chen, L., Tjernberg, L. O., Lundkvist, J., Nilsson, I., & Karlström, H. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.04.006 · Cited by 19
“This is consistent with previously published results [20–24,26].”
BackgroundResultGiau, V. V., Wang, M. J., Bagyinszky, E., Youn, Y. C., An, S. S. A., & Kim, S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.003 · Cited by 16
The 5×FAD mouse model of Alzheimer's disease
Ismeurt, C., Giannoni, P., & Claeysen, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00013-6 · Cited by 24
Rangsinth, P., Duangjan, C., Sillapachaiyaporn, C., Isidoro, C., Prasansuklab, A., & Tencomnao, T. (2021) · Pharmaceuticals · doi:10.3390/ph14090901 · Cited by 16
The Genetics of Alzheimer’s Disease and Parkinson’s Disease
Bekris, L. M., Yu, C., Bird, T. D., & Tsuang, D. W. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_21 · Cited by 19
“PSEN2-associated mutations have been reported to increase the ratio of Aβ42 to Aβ40 (Aβ42/Aβ40) in mice and humans (Citron et al., 1997; Scheuner et al., 1996), indicating that presenilins might modify the way in which γ-secretase cuts APP.”
BackgroundInfluentialSelf-citationEspinoza-Fonseca, M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.218 · Cited by 17
The Role of the Presenilin-1 Homologue Gene sel-12 ofCaenorhabditis elegans in Apoptotic Activities
Kitagawa, N., Shimohama, S., Oeda, T., Uemura, K., Kohno, R., Kuzuya, A., Shibasaki, H., & Ishii, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212058200 · Cited by 17
Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans
Ling, I., Golde, T. E., Galasko, D. R., & Koo, E. H. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0137-y · Cited by 17
“Mutations in PSEN1, PSEN2 and APP genes, causing early onset familial AD (FAD) have been shown to alter Aβ production, with the majority of PSEN mutations elevating the ratio of Aβ42/Aβ40 [9–11].”
BackgroundFalinska, A. M., Bascoul-Colombo, C., Guschina, I. A., Good, M. A., & Harwood, J. L. (2011) · Biocatalysis and Agricultural Biotechnology · doi:10.1016/j.bcab.2011.09.001 · Cited by 17
Chin-Chan, M., Cobos-Puc, L. E., Alvarado-Cruz, I., Bayar, M., & Ermolaeva, M. (2019) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-019-01739-1 · Cited by 18
Pharmacological Mechanisms in Alzheimer's Therapeutics
Cuello, A. C. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3 · Cited by 18
Skaper, S. D., Facci, L., & Giusti, P. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1084-2 · Cited by 17
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.